Puma Biotechnology Inc. (NASDAQ:PBYI) and Achaogen Inc. (NASDAQ:AKAO), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation of the two firms.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Puma Biotechnology Inc.||250.99M||4.79||113.58M||-3.90||0.00|
In table 1 we can see Puma Biotechnology Inc. and Achaogen Inc.’s gross revenue, earnings per share (EPS) and valuation.
Table 2 shows the return on equity, return on assets and net margins of the two firms.
|Net Margins||Return on Equity||Return on Assets|
|Puma Biotechnology Inc.||-45.25%||-430.7%||-105.8%|
Volatility & Risk
A 0.64 beta means Puma Biotechnology Inc.’s volatility is 36.00% less than Standard & Poor’s 500’s volatility. From a competition point of view, Achaogen Inc. has a 0.84 beta which is 16.00% less volatile compared to Standard & Poor’s 500.
The current Quick Ratio of Puma Biotechnology Inc. is 3 while its Current Ratio is 3. Meanwhile, Achaogen Inc. has a Current Ratio of 2.5 while its Quick Ratio is 2.5. Puma Biotechnology Inc. is better positioned to pay off its short-term and long-term debts than Achaogen Inc.
The following table shown below contains the ratings and recommendations for Puma Biotechnology Inc. and Achaogen Inc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Puma Biotechnology Inc.||0||0||0||0.00|
Meanwhile, Achaogen Inc.’s consensus target price is $2.75, while its potential upside is 2,400.00%.
Institutional & Insider Ownership
Roughly 94.9% of Puma Biotechnology Inc. shares are owned by institutional investors while 36.2% of Achaogen Inc. are owned by institutional investors. Insiders owned roughly 11.3% of Puma Biotechnology Inc.’s shares. Competitively, Achaogen Inc. has 16.9% of it’s share owned by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Puma Biotechnology Inc.||40.09%||43.76%||74.41%||-3.88%||-35.09%||96.95%|
For the past year Puma Biotechnology Inc. had bullish trend while Achaogen Inc. had bearish trend.
On 6 of the 10 factors Puma Biotechnology Inc. beats Achaogen Inc.
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care. Its drug candidates include PB272 (neratinib (oral)) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 (neratinib (intravenous)). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Achaogen, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes antibacterials to treat multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin, which is in Phase III clinical trial for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR Enterobacteriaceae comprising carbapenem-resistant Enterobacteriaceae. It is also involved in the research and development of antipseudomonal LpxC inhibitor compounds for the treatment of bacterial infections; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to to enable patients to receive safe and efficacious doses of plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.